Search Results - "Abdallah, Al–Ola"

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study by Lonial, Sagar, Lee, Hans C., Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K., Chari, Ajai, Abdallah, Al‐Ola, Callander, Natalie, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Voorhees, Peter M., Womersley, Lynsey, Baron, January, Piontek, Trisha, Lewis, Eric, Opalinska, Joanna, Gupta, Ira, Cohen, Adam D.

“…Background On the basis of the DREAMM‐2 study (ClinicalTrials.gov identifier NCT03525678), single‐agent belantamab mafodotin (belamaf) was approved for…”
Get full text

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study by Lonial, Sagar, Lee, Hans C, Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K, Chari, Ajai, Abdallah, Al-Ola, Callander, Natalie, Lendvai, Nikoletta, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Karlin, Lionel, Libby, Edward, Arnulf, Bertrand, Facon, Thierry, Hulin, Cyrille, Kortüm, K Martin, Rodríguez-Otero, Paula, Usmani, Saad Z, Hari, Parameswaran, Baz, Rachid, Quach, Hang, Moreau, Philippe, Voorhees, Peter M, Gupta, Ira, Hoos, Axel, Zhi, Eric, Baron, January, Piontek, Trisha, Lewis, Eric, Jewell, Roxanne C, Dettman, Elisha J, Popat, Rakesh, Esposti, Simona Degli, Opalinska, Joanna, Richardson, Paul, Cohen, Adam D

“…Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in…”
Get full text

Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study by Dima, Danai, Rashid, Aliya, Davis, James A., Shune, Leyla, Abdallah, Al‐Ola, Li, Hong, DeJarnette, Shaun, Khouri, Jack, Williams, Louis, Hashmi, Hamza, Raza, Shahzad, McGuirk, Joseph, Anwer, Faiz, Ahmed, Nausheen

“…Summary Ide‐cel received approval for relapsed–refractory multiple myeloma based on the results of the KarMMa‐1 trial. However, patients with significant…”
Get full text

Dampening Logistics Creating Inequitable Access: A Major Threat Despite Advancements by Ayoobkhan, Fathima Shehnaz, Abdallah, Al- Ola, Anwer, Faiz, Ahmed, Nausheen

Get full text

Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis by Etekal, Tommy, Koehn, Kelly, Sborov, Douglas W., McClune, Brian, Prasad, Vinay, Haslam, Alyson, Berger, Katherine, Booth, Christopher, Al Hadidi, Samer, Abdallah, Al‐Ola, Goodman, Aaron, Mohyuddin, Ghulam Rehman

“…Summary Use of surrogate end‐points such as progression‐free survival (PFS) and other time‐to‐event (TTE) end‐points is common in multiple myeloma (MM)…”
Get full text

Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019 by Balmaceda, Nicole, Aziz, Muhammad, Chandrasekar, Viveksandeep Thoguluva, McClune, Brian, Kambhampati, Suman, Shune, Leyla, Abdallah, Al-Ola, Anwer, Faiz, Majeed, Aneela, Qazilbash, Muzaffar, Ganguly, Siddhartha, McGuirk, Joseph, Mohyuddin, Ghulam Rehman

“…Abstract Background Patients with multiple myeloma (MM) remain at an increased risk of infection due to the disease process, as well as the ensuing treatments…”
Get full text

Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma by Abdallah, Al‐Ola, Mahmoudjafari, Zahra, Ahmed, Nausheen, Cui, Wei, Shune, Leyla, McGuirk, Joseph, Mohan, Meera, Mohyuddin, Ghulam Rehman, Afrough, Aimaz, Alkharabsheh, Omar, Atrash, Shebli

“…Daratumumab demonstrates activity as a single agent and in combination with either immunomodulatory agents (IMiDs) or proteasome inhibitors (PIs) in relapsed…”
Get full text

Neutralizing antibody responses against SARS‐CoV‐2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination by Abdallah, Al‐Ola, Mahmoudjafari, Zahra, Atieh, Tahani, Ahmed, Nausheen, Cui, Wei, Shune, Leyla, Mohan, Meera, McGuirk, Joseph, Remker, Cassie, Foss, Margaret, Karloff, Ellie, Fitch, Heather, Atrash, Shebli

“…Many patients with plasma cell disorder (PCD) on active treatment with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) require hospitalization,…”
Get full text

Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma by Dima, Danai, Mansour, Razan, Davis, James A., Minchak, Megan, Goel, Utkarsh, Atallah, Rawan, Logan, Emerson, Tabak, Carine, Rashid, Aliya, Ahmed, Nausheen, Abdallah, Al‐Ola, Hashmi, Hamza

“…Objectives and Methods We conducted a multicenter retrospective study to analyze the safety and efficacy of DPd versus DKd in daratumumab naïve RRMM patients…”
Get full text

Safety and efficacy of B cell maturation antigen‐directed CAR T‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis by Goel, Utkarsh, Dima, Danai, Davis, James, Ahmed, Nausheen, Shaikh, Hira, Lochner, Jonathan, Abdallah, Al‐Ola, Khouri, Jack, Hashmi, Hamza, Anwer, Faiz

“…Clinical trials evaluating chimeric antigen receptor (CAR) T‐cell therapy in relapsed/refractory multiple myeloma (RRMM) have typically excluded patients with…”
Get full text

Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta‐analysis by Mohyuddin, Ghulam Rehman, Aziz, Muhammad, McClune, Brian, Abdallah, Al‐Ola, Qazilbash, Muzaffar

“…Objective Ascertain the benefit of prophylactic antibiotics for patients with newly diagnosed multiple myeloma (MM), given that clinical trials evaluating this…”
Get full text

Hospitalization at the end of life in patients with multiple myeloma by Abbasi, Saqib, Roller, John, Abdallah, Al-Ola, Shune, Leyla, McClune, Brian, Sborov, Douglas, Mohyuddin, Ghulam Rehman

“…Despite advances in treatment, multiple myeloma (MM) remains incurable and results in significant morbidity and mortality. Further research investigating where…”
Get full text

Safety and efficacy of eltrombopag in patients with post‐CAR T cytopenias by Wesson, William, Ahmed, Nausheen, Rashid, Aliya, Tabak, Carine, Logan, Emerson, Marchena‐Burgos, Jose, Nelson, Maggie, Davis, James A., McGann, Mary, Shune, Leyla, Hoffmann, Marc, Abdallah, Al‐Ola, Hashmi, Hamza

“…Background While chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment outcomes of relapsed/refractory hematological malignancies,…”
Get full text

CAR-T treatment for hematological malignancies by Atrash, Shebli, Bano, Kulsum, Harrison, Bradley, Abdallah, Al-Ola

“…Chimeric antigen receptor (CAR)-T-cell therapy has sparked a wave of optimism in hematological malignancies, reflected by the successful results of early…”
Get full text

Multiple myeloma triplet therapies: baseline characteristics and control groups by Mohyuddin, Ghulam Rehman, Abdallah, Al-Ola, McClune, Brian, Goodman, Aaron, Prasad, Vinay

Get full text

Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial by Nooka, Ajay K, Cohen, Adam D, Lee, Hans C, Badros, Ashraf, Suvannasankha, Attaya, Callander, Natalie, Abdallah, Al-Ola, Trudel, Suzanne, Chari, Ajai, Libby, Edward N, Chaudhry, Maria, Hultcrantz, Malin, Kortüm, K Martin, Popat, Rakesh, Sborov, Douglas, Hakim, Shawn, Lewis, Eric, Gorsh, Boris, Bhushan, Bharat, McKeown, Astrid, Gupta, Ira, Opalinska, Joanna, Richardson, Paul G, Lonial, Sagar

“…Patients with relapsed/refractory multiple myeloma (RRMM) have a high unmet treatment need. Belantamab mafodotin (belamaf), a first-in-class, B-cell maturation…”
Get full text

Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review by Mohyuddin, Ghulam Rehman, Koehn, Kelly, Abdallah, Al‐Ola, Sborov, Douglas, Rajkumar, S. Vincent, Kumar, Shaji, McClune, Brian

“…Surrogate endpoints are being used more frequently in randomized controlled trials, even though they do not consistently corelate with patient outcomes. We…”
Get full text

Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia‐related changes: A single institution experience by Gao, Linlin, Hyter, Stephen, Zhang, Da, Kelting, Sarah, Woodroof, Janet, Abdallah, Al‐Ola, Yacoub, Abdulraheem, McGuirk, Joseph, Abdelhakim, Haitham, Godwin, Andrew K., Cui, Wei

“…Introduction Next‐generation sequencing (NGS) analysis showed clonal cytopenia of undetermined significance (CCUS) as an immediate precursor to myelodysplastic…”
Get full text

Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation by Shahzad, Moazzam, Amin, Muhammad Kashif, Bellman, Polina, Al‐Ramahi, Joe, Noor, Jawad, Vyas, Abhinav, Mahmoudjafari, Zahra, McGuirk, Matthew, DeJarnette, Shaun, Ahmed, Nausheen, Abdallah, Al‐Ola, Shune, Leyla, Singh, Anurag K., McGuirk, Joseph P., Abhyankar, Sunil, Mushtaq, Muhammad Umair

“…Background Nivestym, a biosimilar granulocyte colony‐stimulating factor (G‐CSF) to the originator filgrastim (Neupogen), is now being used for the mobilization…”
Get full text

Palliative care utilization, transfusion burden, and end‐of‐life care for patients with multiple myeloma by McInturf, Geoffrey, Younger, Kimberly, Sanchez, Courtney, Walde, Charles, Abdallah, Al‐Ola, Ahmed, Nausheen, Shune, Leyla, Sborov, Douglas W., Godara, Amandeep, McClune, Brian, Sinclair, Christian T., Mohyuddin, Ghulam Rehman

“…Introduction Despite treatment advances, multiple myeloma (MM) remains a significant source of morbidity and mortality. We aimed to examine specialist…”
Get full text